The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

2018 Korean Heart Rhythm Society Guidelines for Antiarrhythmic Drug Therapy in Non-valvular Atrial Fibrillation

2018 대한부정맥학회 비판막성 심방세동 환자의 동율동 조절 약제 지침

  • Kang, Ki-Woon (Department of Cardiology, Eulji University Hospital School of Medicine) ;
  • Shim, Jaemin (Department of Cardiology, Korea University Anam Hospital, Korea University College of Medicine) ;
  • Ahn, Jinhee (Department of Cardiology, Busan National University College of Medicine) ;
  • Lee, Dae In (Department of Cardiology, Chungbuk National University College of Medicine) ;
  • Kim, Jun (Department of Cardiology, Asan Medical Center, Ulsan University College of Medicine) ;
  • Joung, Boyoung (Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine) ;
  • Choi, Kee-Joon (Department of Cardiology, Asan Medical Center, Ulsan University College of Medicine)
  • 강기운 (을지대학교 의과대학 을지대학교병원 심장내과) ;
  • 심재민 (고려대학교 의과대학 고려대학교 안암병원 순환기내과) ;
  • 안진희 (부산대학교 의과대학 부산대학교병원 순환기내과) ;
  • 이대인 (충북대학교 의과대학 충북대학교 병원 심장내과) ;
  • 김준 (울산대학교 의과대학 서울아산병원 심장내과) ;
  • 정보영 (연세대학교 의과대학 세브란스병원 심장내과) ;
  • 최기준 (울산대학교 의과대학 서울아산병원 심장내과)
  • Published : 2018.04.01
⟨ Previous Next ⟩

Abstract

Rhythm control therapy is the main strategy for restoring and maintaining sinus rhythm in patients with non-valvular atrial fibrillation (NVAF). Sinus rhythm is better restored and maintained with antiarrhythmic drugs than with placebo treatment. In addition, catheter ablation or combination therapy is more effective than antiarrhythmic drugs for treating NVAF. However, in most clinical trials to date, rhythm control therapy has resulted in neutral clinical outcomes compared with rate control therapy. The decision to undergo rhythm control therapy should be based on age, atrial fibrillation (AF)-related symptoms, type of AF, structural heart disease, and underlying comorbidities. For now, rhythm control therapy is indicated to improve symptoms in patients with NVAF who have refractory symptoms after adequate rate control therapy. The Korean Heart Rhythm Society organized the Korean AF Management Guideline Committee and analyzed all available data, including South Korean patients with NVAF. This review article provides general principles and detailed methodology for rhythm control therapy in South Korean patients with NVAF.

Keywords

References

  1. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2012;(5):CD005049.
  2. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-920. https://doi.org/10.1056/NEJM200003303421302
  3. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-2677. https://doi.org/10.1056/NEJMoa0708789
  4. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357:987-999. https://doi.org/10.1056/NEJMoa054686
  5. Kirchhof P, Andresen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012;380:238-246. https://doi.org/10.1016/S0140-6736(12)60570-4
  6. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010;303:333-340. https://doi.org/10.1001/jama.2009.2029
  7. Arbelo E, Brugada J, Hindricks G, et al. The atrial fibrillation ablation pilot study: a European Survey on methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J 2014;35:1466-1478. https://doi.org/10.1093/eurheartj/ehu001
  8. Anselmino M, Matta M, D'Ascenzo F, et al. Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis. Circ Arrhythm Electrophysio 2014;7:1011-1018. https://doi.org/10.1161/CIRCEP.114.001938
  9. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-678. https://doi.org/10.1056/NEJMoa0803778
  10. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833. https://doi.org/10.1056/NEJMoa021328
  11. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840. https://doi.org/10.1056/NEJMoa021375
  12. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004;126:476-486. https://doi.org/10.1378/chest.126.2.476
  13. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med 2014;160:760-773. https://doi.org/10.7326/M13-1467
  14. Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol 2013;36:122-133. https://doi.org/10.1111/j.1540-8159.2012.03513.x
  15. de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005;165:258-262. https://doi.org/10.1001/archinte.165.3.258
  16. Kotecha D, Kirchhof P. Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed. Evid Based Med 2014;19:222-223. https://doi.org/10.1136/ebmed-2014-110062
  17. Kirchhof P, Breithardt G, Camm AJ, et al. Improving outcomes in patients with atrial fibrillation: rationale and design of the early treatment of atrial fibrillation for stroke prevention trial. Am Heart J 2013;166:442-448. https://doi.org/10.1016/j.ahj.2013.05.015
  18. Shi LZ, Heng R, Liu SM, Leng FY. Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: a meta-analysis of randomized controlled trials. Exp Ther Med 2015;10:816-822. https://doi.org/10.3892/etm.2015.2545
  19. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003;87:121-128. https://doi.org/10.1016/S0167-5273(02)00467-9
  20. Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003;41:255-262.
  21. Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med 2003;163:777-785. https://doi.org/10.1001/archinte.163.7.777
  22. Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003;89:239-248. https://doi.org/10.1016/S0167-5273(02)00477-1
  23. Thomas SP, Guy D, Wallace E, et al. Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial. Am Heart J 2004;147:E3. https://doi.org/10.1016/S0002-8703(03)00526-X
  24. Vijayalakshmi K, Whittaker VJ, Sutton A, et al. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. Am Heart J 2006;151:863.e1-e6. https://doi.org/10.1016/j.ahj.2005.09.009
  25. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-1872. https://doi.org/10.1056/NEJMoa041705
  26. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008;117:1518-1525. https://doi.org/10.1161/CIRCULATIONAHA.107.723866
  27. Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:652-659. https://doi.org/10.1161/CIRCEP.109.870204
  28. Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57:313-321. https://doi.org/10.1016/j.jacc.2010.07.046
  29. Bash LD, Buono JL, Davies GM, et al. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation. Cardiovasc Drugs Ther 2012;26:167-179. https://doi.org/10.1007/s10557-012-6374-4
  30. Cristoni L, Tampieri A, Mucci F, et al. Cardioversion of acute atrial fibrillation in the short observation unit: comparison of a protocol focused on electrical cardioversion with simple antiarrhythmic treatment. Emerg Med J 2011;28:932-937. https://doi.org/10.1136/emj.2009.083196
  31. Gitt AK, Smolka W, Michailov G, Bernhardt A, Pittrow D, Lewalter T. Types and outcomes of cardioversion in patients admitted to hospital for atrial fibrillation: results of the German RHYTHM-AF Study. Clin Res Cardiol 2013;102:713-723. https://doi.org/10.1007/s00392-013-0586-x
  32. Bellone A, Etteri M, Vettorello M, et al. Cardioversion of acute atrial fibrillation in the emergency department: a prospective randomised trial. Emerg Med J 2012;29:188-191. https://doi.org/10.1136/emj.2010.109702
  33. Crijns HJ, Weijs B, Fairley AM, et al. Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study. Int J Cardiol 2014;172:588-594. https://doi.org/10.1016/j.ijcard.2014.01.099
  34. Lip GY, Gitt AK, Le Heuzey JY, et al. Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study). Am J Cardiol 2014;113:480-484. https://doi.org/10.1016/j.amjcard.2013.10.036
  35. Reisinger J, Gatterer E, Lang W, et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 2004;25:1318-1324. https://doi.org/10.1016/j.ehj.2004.04.030
  36. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996;94:1613-1621. https://doi.org/10.1161/01.CIR.94.7.1613
  37. Reisinger J, Gatterer E, Heinze G, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998;81:1450-1454. https://doi.org/10.1016/S0002-9149(98)00223-9
  38. Mun HS, Shen C, Pak HN, et al. Chronic amiodarone therapy impairs the function of the superior sinoatrial node in patients with atrial fibrillation. Circ J 2013;77:2255-2263. https://doi.org/10.1253/circj.CJ-12-1615
  39. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004;351:2384-2391. https://doi.org/10.1056/NEJMoa041233
  40. Saborido CM, Hockenhull J, Bagust A, Boland A, Dickson R, Todd D. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy. Health Technol Assess 2010;14:iii-iv, 1-75.
  41. Kirchhof P, Monnig G, Wasmer K, et al. A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur Heart J 2005;26:1292-1297. https://doi.org/10.1093/eurheartj/ehi160
  42. Mittal S, Ayati S, Stein KM, et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation 2000;101:1282-1287. https://doi.org/10.1161/01.CIR.101.11.1282
  43. Kirchhof P, Eckardt L, Loh P, et al. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 2002;360:1275-1279. https://doi.org/10.1016/S0140-6736(02)11315-8
  44. Furniss SS, Sneyd JR. Safe sedation in modern cardiological practice. Heart 2015;101:1526-1530. https://doi.org/10.1136/heartjnl-2015-307656
  45. Alp NJ, Rahman S, Bell JA, Shahi M. Randomised comparison of antero-lateral versus antero-posterior paddle positions for DC cardioversion of persistent atrial fibrillation. Int J Cardiol 2000;75:211-216. https://doi.org/10.1016/S0167-5273(00)00326-0
  46. Singh SN, Tang XC, Reda D, Singh BN. Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. Heart Rhythm 2009;6:152-155. https://doi.org/10.1016/j.hrthm.2008.10.036
  47. Channer KS, Birchall A, Steeds RP, et al. A randomized placebo- controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J 2004;25:144-150. https://doi.org/10.1016/j.ehj.2003.10.020
  48. Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M, Santini M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol 1996;28:700-706. https://doi.org/10.1016/0735-1097(96)00230-6
  49. Hemels ME, Van Noord T, Crijns HJ, et al. Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. J Am Coll Cardiol 2006;48:1001-1009. https://doi.org/10.1016/j.jacc.2006.05.043
  50. Villani GQ, Piepoli MF, Terracciano C, Capucci A. Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled study. Am Heart J 2000;140:e12.
  51. De Simone A, Stabile G, Vitale DF, et al. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999;34:810-814. https://doi.org/10.1016/S0735-1097(99)00256-9
  52. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J 1997;18:649-654. https://doi.org/10.1093/oxfordjournals.eurheartj.a015311
  53. Atarashi H, Inoue H, Fukunami M, et al. Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation. Circ J 2002;66:553-556. https://doi.org/10.1253/circj.66.553
  54. Hansen ML, Jepsen RM, Olesen JB, et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace 2015;17:18-23. https://doi.org/10.1093/europace/euu189
  55. Schadlich PK, Schmidt-Lucke C, Huppertz E, et al. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany. Am J Cardiovasc Drugs 2007;7:199-217. https://doi.org/10.2165/00129784-200707030-00006
  56. Schmidt-Lucke C, Paar WD, Stellbrink C, et al. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Thromb Res 2007;119:27-34. https://doi.org/10.1016/j.thromres.2005.11.016
  57. Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004;109:997-1003. https://doi.org/10.1161/01.CIR.0000120509.64740.DC
  58. Shin DG, Cho I, Hartaigh B, et al. Cardiovascular events of electrical cardioversion under optimal anticoagulation in atrial fibrillation: the multicenter analysis. Yonsei Med J 2015;56:1552-1558. https://doi.org/10.3349/ymj.2015.56.6.1552
  59. Kim TH, Yang PS, Kim D, et al. CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke: a Korean nationwide cohort study. Stroke 2017;48:2984-2990. https://doi.org/10.1161/STROKEAHA.117.018551
  60. Nuotio I, Hartikainen JE, Gronberg T, Biancari F, Airaksinen KE. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA 2014;312:647-649. https://doi.org/10.1001/jama.2014.3824
  61. Lafuente-Lafuente C, Valembois L, Bergmann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2015;(3):CD005049.
  62. Darkner S, Chen X, Hansen J, et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). Eur Heart J 2014;35:3356-3364. https://doi.org/10.1093/eurheartj/ehu354
  63. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. survival trial of antiarrhythmic therapy in congestive heart failure. N Engl J Med 1995;333:77-82. https://doi.org/10.1056/NEJM199507133330201
  64. Kirchhof P, Franz MR, Bardai A, Wilde AM. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol 2009;54:143-149. https://doi.org/10.1016/j.jacc.2009.03.043
  65. Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart rhythm 2007;4:1250-1259. https://doi.org/10.1016/j.hrthm.2007.07.020
  66. Ahmed S, Rienstra M, Crijns HJ, et al. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA 2008;300:1784-1792. https://doi.org/10.1001/jama.300.15.1784
  67. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-2687. https://doi.org/10.1056/NEJMoa0800456
  68. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-2276. https://doi.org/10.1056/NEJMoa1109867
  69. Tschuppert Y, Buclin T, Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007;64:785-791.
  70. Van Gelder IC, Crijns HJ, Van Gilst WH, Van Wijk LM, Hamer HP, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989;64:1317-1321. https://doi.org/10.1016/0002-9149(89)90574-2
  71. Echt D, Liebson P, Mitchell L, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788. https://doi.org/10.1056/NEJM199103213241201
  72. Aliot E, Capucci A, Crijns HJ, Goette A, Tamargo J. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace 2011;13:161-173. https://doi.org/10.1093/europace/euq382
  73. Gulizia M, Mangiameli S, Orazi S, et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the prevention investigation and treatment: a group for observation and research on atrial arrhythmias (PITAGORA) trial. Am Heart J 2008;155:100-107, 107.e1.
  74. Chimienti M, Cullen MT Jr, Casadei G. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. report from the flecainide and propafenone Italian study (FAPIS) group. Eur Heart J 1995;16:1943-1951. https://doi.org/10.1093/oxfordjournals.eurheartj.a060852
  75. Kim DS, Koh CW, Cho HK, et al. Comparision of thr efficacy of propafenone and flecainide in patients with atrial fibrillation. Korean Circ J 1997;27:860-866. https://doi.org/10.4070/kcj.1997.27.9.860
  76. Pritchett EL, Page RL, Carlson M, Undesser K, Fava G; Rythmol Atrial Fibrillation Trial (RAFT) Investigators. Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol 2003;92:941-946. https://doi.org/10.1016/S0002-9149(03)00974-3
  77. Capucci A, Piangerelli L, Ricciotti J, Gabrielli D, Guerra F. Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation. Europace 2016;18:1698-1704. https://doi.org/10.1093/europace/euv462
  78. Kochiadakis GE, Igoumenidis NE, Parthenakis FI, Chlouverakis GI, Vardas PE. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1999;33:966-971. https://doi.org/10.1016/S0735-1097(98)00678-0
  79. Bellandi F, Simonetti I, Leoncini M, et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol 2001;88:640-645. https://doi.org/10.1016/S0002-9149(01)01806-9
  80. Kochiadakis GE, Igoumenidis NE, Hamilos MI, et al. Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest 2004;125:377-383. https://doi.org/10.1378/chest.125.2.377
  81. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. propafenone atrial fibrillation trial investigators. Am J Cardiol 1997;79:418-423. https://doi.org/10.1016/S0002-9149(96)00779-5
  82. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 2011;13:329-345. https://doi.org/10.1093/europace/euq450
  83. Chun KJ, Byeon K, Im SI, et al. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. Clin Ther 2014;36:1169-1175. https://doi.org/10.1016/j.clinthera.2014.07.013
  84. Plosker GL. Pilsicainide. Drugs 2010;70:455-467. https://doi.org/10.2165/11204960-000000000-00000
  85. Shiga T, Yoshioka K, Watanabe E, et al. Paroxysmal atrial fibrillation recurrences and quality of life in symptomatic patients: a crossover study of flecainide and pilsicainide. J Arrhythm 2017;33:310-317. https://doi.org/10.1016/j.joa.2017.03.005
  86. Gallik DM, Kim SG, Ferrick KJ, Roth JA, Fisher JD. Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. Am Heart J 1997;134:155-160. https://doi.org/10.1016/S0002-8703(97)70118-2
  87. Alt E, Ammer R, Lehmann G, et al. Patient characteristics and underlying heart disease as predictors of recurrent atrial fibrillation after internal and external cardioversion in patients treated with oral sotalol. Am Heart J 1997;134:419-425. https://doi.org/10.1016/S0002-8703(97)70076-0
  88. Piccini JP, Al-Khatib SM, Wojdyla DM, et al. Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. Am J Cardiol 2014;114:716-722. https://doi.org/10.1016/j.amjcard.2014.06.004
  89. Reiffel JA, Appel G. Importance of QT interval determination and renal function assessment during antiarrhythmic drug therapy. J Cardiovasc Pharmacol Ther 2001;6:111-119. https://doi.org/10.1177/107424840100600202
  90. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686-690. https://doi.org/10.1161/01.CIR.81.2.686
  91. Husser D, Stridh M, Sornmo L, et al. Time-frequency analysis of the surface electrocardiogram for monitoring antiarrhythmic drug effects in atrial fibrillation. Am J Cardiol 2005;95:526-528. https://doi.org/10.1016/j.amjcard.2004.10.025
  92. Kim BH, Kim JR, Lim KS, et al. An open-label, single-dose, parallel-group, dose-increasing study comparing the pharmacokinetics and tolerability of pilsicainide hydrochloride in healthy Korean and Japanese male subjects. Clin Ther 2009;31:609-618. https://doi.org/10.1016/j.clinthera.2009.03.015
  93. Torres V, Tepper D, Flowers D, et al. QT prolongation and the antiarrhythmic efficacy of amiodarone. J Am Coll Cardiol 1986;7:142-147. https://doi.org/10.1016/S0735-1097(86)80272-8
  94. Cobbe SM. Clinical usefulness of the Vaughan Williams classification system. Eur Heart J 1987;8 Suppl A:65-69.
  95. Feld GK, Chen PS, Nicod P, Fleck RP, Meyer D. Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs. Am J Cardiol 1990;66:378-383. https://doi.org/10.1016/0002-9149(90)90856-V
  96. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363-1372. https://doi.org/10.1136/heart.89.11.1363
  97. Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010;121:1047-1060. https://doi.org/10.1161/CIRCULATIONAHA.109.192704
  98. Naccarelli GV, Wolbrette DL, Levin V, et al. Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter. Clin Med Insights Cardiol 2011;5:103-119.
  99. Fetsch T, Bauer P, Engberding R, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004;25:1385-1394. https://doi.org/10.1016/j.ehj.2004.04.015
  100. Burashnikov A, Pourrier M, Gibson JK, Lynch JJ, Antzelevitch C. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Circ Arrhythm Electrophysiol 2012;5:400-408. https://doi.org/10.1161/CIRCEP.111.968305
  101. Simon A, Niederdoeckl J, Skyllouriotis E, et al. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department. Europace 2017;19:233-240.
  102. Martin RI, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart 2014;100:1506-1510. https://doi.org/10.1136/heartjnl-2014-305482
  103. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-1839. https://doi.org/10.1016/j.jacc.2004.11.070
  104. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010;55:2299-2307. https://doi.org/10.1016/j.jacc.2010.01.043
  105. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559. https://doi.org/10.1056/NEJMoa0801317
  106. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. https://doi.org/10.1056/NEJMoa1409077
  107. Williams RS, deLemos JA, Dimas V, Reisch J, Hill JA, Naseem RH. Effect of spironolactone on patients with atrial fibrillation and structural heart disease. Clin Cardiol 2011;34:415-419. https://doi.org/10.1002/clc.20914
  108. Swedberg K, Zannad F, McMurray JJ, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012;59:1598-1603. https://doi.org/10.1016/j.jacc.2011.11.063
  109. Kotecha D, Holmes J, Krum H, et al. Efficacy of ${\beta}$ blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:2235-2243. https://doi.org/10.1016/S0140-6736(14)61373-8
  110. Nergardh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study. Eur Heart J 2007;28:1351-1357. https://doi.org/10.1093/eurheartj/ehl544
  111. Van Noord T, Tieleman RG, Bosker HA, et al. Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension. Europace 2004;6:343-350. https://doi.org/10.1016/j.eupc.2004.04.001
  112. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008;51:828-835. https://doi.org/10.1016/j.jacc.2007.09.063
  113. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008;126:160-170. https://doi.org/10.1016/j.ijcard.2007.07.137
  114. Zheng Z, Jayaram R, Jiang L, et al. Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med 2016;374:1744-1753. https://doi.org/10.1056/NEJMoa1507750
  115. Zhang B, Zhen Y, Tao A, Bao Z, Zhang G. Polyunsaturated fatty acids for the prevention of atrial fibrillation after cardiac surgery: an updated meta-analysis of randomized controlled trials. J Cardiol 2014;63:53-59. https://doi.org/10.1016/j.jjcc.2013.06.014
  116. Mozaffarian D, Marchioli R, Macchia A, et al. Fish oil and postoperative atrial fibrillation: the Omega-3 fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA 2012;308:2001-2011. https://doi.org/10.1001/jama.2012.28733
  117. Macchia A, Grancelli H, Varini S, et al. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll Cardiol 2013;61:463-468. https://doi.org/10.1016/j.jacc.2012.11.021

Cited by

  1. Inhibition of voltage-dependent K+ current in rabbit coronary arterial smooth muscle cells by the class Ic antiarrhythmic drug propafenone vol.22, pp.5, 2018, https://doi.org/10.4196/kjpp.2018.22.5.597
  2. Guideline of atrial fibrillation management vol.62, pp.5, 2019, https://doi.org/10.5124/jkma.2019.62.5.265